The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer

doi:10.6515/ACS20151023A

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/30991

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/30991

Title:	The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer
Authors:	Chang, Wei-Ting Shih, Jhih-Yuan Feng, Yin-Hsun Chiang, Chun-Yen Kuo, Yu Hsuan Chen, Wei-Yu Wu, Hong-Chang Cheng, Juei-Tang Wang, Jhi-Joung Chen, Zhih-Cherng
Contributors:	Chi Mei Med Ctr, Div Cardiol, Dept Internal Med Southern Taiwan Univ Sci & Technol, Dept Biotechnol Chi Mei Med Ctr, Dept Internal Med, Div Oncol Chi Mei Med Ctr, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Pharm
Keywords:	Dyspnea Epirubicin Right ventricle Speckle-tracking echocardiography dysfunction
Date:	2016-09
Issue Date:	2018-01-18 11:39:23 (UTC+8)
Publisher:	Taiwan Soc Cardiology
Abstract:	Background: As cancer therapies have improved, patient life spans have been extended but quality of life has been threatened by chemotherapy induced cardiotoxicity. Most cardiac complications remain unobserved until specific symptoms develop. Speckle-tracking echocardiography is a sensitive imaging modality in detecting early occult myocardial dysfunction. Methods: A total number of 35 patients newly diagnosed with breast cancer and preparing for epirubicin therapy were prospectively recruited. Echocardiography, including speckle-tracking echocardiography, was performed sequentially at baseline (T1), after the first cycle (T2) and after the third cycle (T3) of epirubicin. At each visit, the severity of dyspnea was evaluated by the assessment scale. Results: Compared with the baseline, right ventricular longitudinal strain (RVLS_FW) at T2 significantly declined (-22.49 +/- 4.97 vs. -18.48 +/- 4.46, p = 0.001), which was also positively associated with the development of dyspnea (R-2 = 0.8, p = 0.01). At T3, both the left ventricular global longitudinal strain and RVLS_FW were significantly impaired (-21.4 +/- 4.12 vs.-16.94 +/- 6.81%; -22.49 +/- 4.97 vs. -16.86 +/- 7.27%, p = 0.01; 0.001, respectively). Also, the accumulating dose of epirubicin positively correlated with the development of dyspnea (R-2 = 0.38, p = 0.04) and the decline of RVLS_FW (R-2 = 0.53, p = 0.02). Notably, compared with the other echocardiographic parameters only RVLS_FW at the early stage (T2) significantly correlated with the development of dyspnea (odds ratio: 1.84, 95% confidence interval: 1.22-2.78, p = 0.04). Conclusions: RVLS_FW sensitively predicts dyspnea development in breast cancer patients receiving epirubicin therapy. However, larger scale studies are required to validate its role in long-term patient survival.
Relation:	Acta Cardiologica Sinica, v.32 n.5, pp.550-559
Appears in Collections:	[Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
30991.pdf		544Kb	Adobe PDF	317	View/Open
index.html		0Kb	HTML	1062	View/Open

Loading...